AOD-9604 vs Glutathione

Heffernan et al. (Endocrinology 2001) compared hGH and AOD9604 over 14 days in obese mice and in β3-adrenergic-receptor knockout mice. Both raised the repressed β3-AR expression in obese mice, but neither changed body weight or lipolysis in the knockout mice over the long-term protocol, leading the authors to conclude the lipolytic actions were not mediated directly through β3-AR.

Ng et al. (Horm Res 2000) studied oral administration of AOD9604 in obese Zucker rats, reporting reduced body-weight gain and increased adipose lipolytic activity, and — unlike intact hGH — no impairment of insulin sensitivity on euglycaemic clamp.

Stier et al. (J Endocrinol Metab 2013) pooled six randomised, double-blind, placebo-controlled trials and reported no change in serum IGF-1, no adverse effect on carbohydrate metabolism, and no anti-AOD9604 antibodies in tested participants. The same development programme did not show a clinically meaningful weight outcome.

Kwon and Park (Ann Clin Lab Sci 2015) gave intra-articular AOD9604, with or without hyaluronic acid, in a collagenase-induced knee osteoarthritis model in rabbits and scored cartilage morphology, histology and lameness.

Glutathione is the most abundant low-molecular-weight thiol in most cells, and the ratio of reduced to oxidised glutathione is widely used as a read-out of oxidative stress in cell-culture and tissue studies.

Meister and Anderson (Annu Rev Biochem 1983) reviewed glutathione synthesis by γ-glutamylcysteine synthetase and glutathione synthetase, and its breakdown by γ-glutamyl transpeptidase — the framework most synthesis and turnover studies still use.

GSTs conjugate glutathione to electrophilic compounds, and this conjugation step is a standard model in xenobiotic-metabolism research.

Glutathione peroxidases use GSH to reduce hydrogen peroxide and lipid hydroperoxides, with glutathione reductase recycling GSSG back to GSH using NADPH — a common model for studying peroxide handling in vitro.